Plasma methylation test for detecting liver cancer recurrence (GNB4 and Riplet)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, blinded comparative protocol followed patients with primary liver cancer after hepatectomy, liver transplantation, ablation, or TACE and measured plasma methylation of GNB4 and Riplet using a fluorescent PCR kit. Results from the methylation kit were compared, with site blinding, to a clinical reference standard defined by the treating physician's comprehensive diagnosis based on guidelines and other clinical data. The main goal was to characterize the assay's clinical performance for diagnosing recurrence and to validate its use for post-treatment monitoring. Exclusions included concurrent other malignancies, ineligibility for the listed therapies, or negative methylation status before treatment, and the work was conducted at Tongji Hospital in Wuhan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary liver cancer

Exclusion Criteria:

* Concurrent other malignant tumors;
* Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy;
* Negative methylation status prior to treatment.

Where it's running

• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Tingting Li, phD
• Email: litingting@amswh.com
• Phone: +86 13317163570

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Combining advanced ultrasound and molecular analyses to map tumor differences in liver cancer

  This project tries combining multiple ultrasound techniques with molecular (multi-omics) tests to see if they can better characterize tumors and guide care for adults with primary liver cancer who are scheduled for surgery.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07101237

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

• Comparing two treatments for inoperable primary liver cancer

  This study is testing which treatment works better for people with inoperable primary liver cancer by comparing stereotactic radiosurgery and radiofrequency ablation.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06766643

• Evaluation of the HistoSonics Edison System for treating liver tumors

  This study is testing how well the HistoSonics Edison System works for treating liver tumors and how different factors affect the treatment's success in real patients.

  Recruiting at 32 sites HistoSonics, Inc. · Mobile, Alabama and 34 other locations · NCT06486454

• Evaluating a protein as a marker for liver cancer recurrence

  This study is trying to see if higher levels of a certain protein in the blood can help predict if liver cancer will come back in people who have already had it.

  Recruiting Nanjing Medical University · Nanjing, Jiangsu · NCT06430983

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.